Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Hilde De Winter, Filip Callewaert

Blood Adv (2021) 5 (8): 2137–2141.

https://doi.org/10.1182/bloodadvances.2020001834

Published: 2021

Includes: Supplemental data

Journal Articles

Concizumab: a novel anti-TFPI therapeutic for hemophilia

Amy D. Shapiro

Blood Adv (2021) 5 (1): 279.

https://doi.org/10.1182/bloodadvances.2019001140

Published: 2021

Includes: Supplemental data

Journal Articles

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Miney Paquette, Daniel M. Witt, Anne Holbrook, Jane Skov, Jack Ansell, Holger J. Schünemann, Wojtek Wiercioch, Robby Nieuwlaat

Blood Adv (2019) 3 (10): 1638–1646.

https://doi.org/10.1182/bloodadvances.2019000067

Published: 2019

Includes: Supplemental data

Journal Articles

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

Matteo Rota, Paolo A. Cortesi, Roberto Crea, Alessandro Gringeri, Lorenzo G. Mantovani

Blood Adv (2017) 1 (26): 2637–2642.

https://doi.org/10.1182/bloodadvances.2017011536

Published: 2017

Journal Articles

A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management

Chakri Gavva, Ravindra Sarode, Ayesha Zia

Blood Adv (2017) 1 (25): 2386–2391.

https://doi.org/10.1182/bloodadvances.2017009514

Published: 2017

NARROW

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Concizumab: a novel anti-TFPI therapeutic for hemophilia

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management

Email alerts

ASH Publications

American Society of Hematology

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Concizumab: a novel anti-TFPI therapeutic for hemophilia

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only